Alessandro D. Santin MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Clinical Interests

Cancer of the ovary, uterus, vagina, cervix and vulva; Intraperitoneal chemotherapy; Tumor immunology and immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in Gynecologic Oncology


Board Certifications

1993
Obstetrics & Gynecology, FB

Patient Care Locations

alessandro_santinfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, and PancreasA Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

More Clinical Trials...

Edit Profile